Exousia AI Ludwig Enterprises Subsidiary Launches Liposome Research Program
SPARKS, NV / ACCESSWIRE / January 9, 2024 / Ludwig Enterprises, Inc, (OTC:LUDG): A US based biotechnology company with a mission to develop cargo delivery platforms containing genetic mRNA and DNA, and nutritional compounds is pleased to announce that its subsidiary Exousia AI has signed a contract with Eternapure LLC, Howey in the Hills, Florida regarding research and development of Liposome delivery systems. Exousia scientists are using unique proprietary delivery system research combined with machine learning artificial intelligence (AI) to study efficacy of Liposomal delivery of nutritional molecules.
“This is a wonderful beginning to 2024 for our company’s research and manufacturing program,” stated Marvin S. Hausman MD, CEO. “This research contract is a very positive step forward and we anticipate consummating additional similar arrangements.”
Dorian Farmer, Eternapure CEO, said ” We are excited about forging forward in a research and development relationship with Exousia and Dr Hausman. It is my opinion Exousia has game-changing technology to assist us in our long-term plans to develop Chondroitin 4 sulfate as a significant natural anti-inflammatory agent.
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. (Ludwig) is a healthcare holding company focused on cutting edge mRNA genomic technology, therapeutics, and nutraceuticals. Through its subsidiary Exousia AI, the company is developing an Exosomal Targeted Cargo Delivery Platform™. This transformational platform technology combined with machine learning artificial intelligence (AI) will lead to the creation of new therapeutics and improve the efficacy of existing treatments.
Precision Genomics, a Ludwig subsidiary, has a patent pending on the mRNA Inflammatory Index™ that measures 48 different biomarkers of inflammation. Combined with AI and machine learning this technology may enable healthcare professionals to identify sources of chronic inflammation and potentially prevent illnesses such as diabetes, COPD, heart disease and cancer. NuGenea™, a scientifically formulated nutraceutical, supported by decades of independent research into the anti-inflammatory properties of its compounds, is manufactured by the Ludwig subsidiary mRNAforLife, Inc and it’s My RNA for Life™ product line of nutraceuticals.
Advancements in medical technology have awarded us with cutting-edge genomic tools, unheard of even a generation ago. These genomic tools have the potential to not only detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era of medicine with their proprietary mRNA genomic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including, but not limited to heart disease, diabetes, preeclampsia, and cancer. This early detection may allow doctors to take steps to diagnose and manage illness before it progresses and causes serious health problems. Ludwig’s innovative non-invasive testing approach is not only practical but also has the potential to save the healthcare industry millions of dollars in costs. With a virtually untapped market and a billion-dollar healthcare industry, Ludwig and its subsidiaries are poised to significantly impact how we think about disease and live longer healthier lives. For more information please visit: http://www.ludwigent.com.
SAFE HARBOR
Forward-looking statements in this release are made under the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.’s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Ludwig Enterprises, Inc.
Marvin S. Hausman MD, CEO
CEO@LUDG.US
www.ludwigent.com
SOURCE: Ludwig Enterprises, Inc.
View the original press release on accesswire.com
